You have read all your free articles, to continue reading subscribe to read the rest of this content.
Targovax has announced that the combination of ONCOS-102 and pembrolizumab (Keytruda) has demonstrated 35% best objective response rate (ORR) in anti-PD1 refractory malignant melanoma. In this two-part, open label phase 1 trial the combination of ONCOS-102 and the anti-PD1 checkpoint inhibitor (CAlready a subscriber Login You have read all your…
Medivir communicates an update on the status of the development of JNJ-4178, the triple combination of simeprevir, odalasvir and AL-335, following The International Liver Congress 2017 of the European Association for the Study of the Liver (EASL), which was held in Amsterdam, on 19-23 April. DataAlready a subscriber Login You…
New research shows that ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including Amyothrophic Lateral Sclerosis (ALS). TikoMed has announced the publication in Frontiers in Phamacology of peeAlready a subscriber Login You have read all your free articles,…
BioInvent International announces that the FDA has completed the safety review of its Investigational New Drug (IND) application and have concluded that the proposed pediatric clinical investigation can proceed. The IND application is for a Phase I/IIa study that will evaluate the efficacy and saAlready a subscriber Login You have…
